Effect of mesenchymal stem cells and melatonin on experimentally induced peripheral nerve injury in rats

• Published in: Biomedicine & pharmacotherapy Vol. 177; p. 117015
• Main Authors: Khodir, Suzan A., Imbaby, Samar, Abdel Allem Amer, Mohamed Shebl, Atwa, Maha M., Ashour, Fawzy Ahmed, Elbaz, Amani A.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.08.2024; Elsevier
• Subjects: BDNF; EMG; Melatonin; Mesenchymal stem cells; Nerve conduction velocity; Sciatic function index (SFI); Sciatic function index (SFI); Melatonin; BDNF; EMG; Nerve conduction velocity; Mesenchymal stem cells
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.117015

Injury of a peripheral nerve (PNI) leads to both ischemic and inflammatory alterations. Sciatic nerve injury (SNI) represents the most widely used model for PNI. Mesenchymal stem cell-based therapy (MSCs) has convenient properties on PNI by stimulating the nerve regeneration. Melatonin has cytoprotective activity. The neuroprotective characteristics of MSCs and melatonin separately or in combination remain a knowledge need. In the rats-challenged SNI, therapeutic roles of intralesional MSCs and intraperitoneal melatonin injections were evaluated by functional assessment of peripheral nerve regeneration by walking track analysis involving sciatic function index (SFI) and two electrophysiological tests, electromyography and nerve conduction velocity, as well as measurement of antioxidant markers in serum, total antioxidant capacity (TAC) and malondialdehyde, and mRNA expression of brain derived neurotrophic factor (BDNF) in nerve tissues in addition to the histopathological evaluation of nerve tissue. Both individual and combination therapy with MSCs and melatonin therapies could effectively ameliorate this SNI and promote its regeneration as evidenced by improving the SFI and two electrophysiological tests and remarkable elevation of TAC with decline in lipid peroxidation and upregulation of BDNF levels. All of these led to functional improvement of the damaged nerve tissues and good recovery of the histopathological sections of sciatic nerve tissues suggesting multifactorial synergistic approach of the concurrent usage of melatonin and MSCs in PNI. The combination regimen has the most synergistic neuro-beneficial effects in PNI that should be used as therapeutic option in patients with PNI to boost their quality of life. [Display omitted] •Melatonin and MSCs could effectively ameliorate sciatic nerve injury (SNI) and promote its regeneration.•Concurrent usage of melatonin and MSCs led to functional improvement of the damaged nerve tissues.•Melatonin and MSCs upregulated the BDNF levels and had anti-oxidant effects in injured nerve tissues.•Melatonin and MSCs therapies led to good recovery of the SNI-induced histopathological alterations.•The neuroprotective effects of the combination therapy of MSCs and melatonin in SNI model were proven.